A company’s final score for a given year represents an equal contribution of: 1) public availability of trials in patients; 2) compliance with legal transparency requirements; and 3) patient-level data sharing. If a company has more than one approved medicine in a given year, its final score represents an average of all of its approved medicines for that year.

A complete description of the methodology for reporting years is available below.

2017 Methodology

2017 Dataset

2015 Methodology

2015 Dataset